Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2/3 1Phase 1/2 1

Status

Completed 35Terminated 17Unknown 10Recruiting 8Active not recruiting 7Withdrawn 6Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Lymphoid 7

Conditions

Lymphoma, Large B-Cell, Diffuse 32Lymphoma, Follicular 25Lymphoma, Mantle-Cell 23Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Non-Hodgkin 21Lymphoma, B-Cell 16Lymphoma, B-Cell, Marginal Zone 13Neoplasms 8Recurrence 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia 5Burkitt Lymphoma 5Neoplasm, Residual 3Lymphoproliferative Disorders 3Leukemia, Hairy Cell 3Hematologic Diseases 3Myelodysplastic Syndromes 2Lymphoma, AIDS-Related 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Blast Crisis 2Sarcoma, Myeloid 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neuritis 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myeloid Diseases 1

Interventions

Dexamethasone 18Cyclophosphamide 16fludarabine 11pomalidomide 9pembrolizumab 9carfilzomib 9daratumumab 7Rituximab 7Lenalidomide 7Calcium Dobesilate 7fludarabine phosphate 6Cisplatin 6Bortezomib 6Gemcitabine 5venetoclax 4elotuzumab 4isatuximab 3Vincristine 3Radiotherapy 3Prednisone 3Letrozole 3Etoposide 3Doxorubicin 3Cytarabine 3tisagenlecleucel 2selinexor 2ruxolitinib 2palbociclib 2ixazomib 2dexamethasone 21-phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × Rituximab × Clear all
NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Karyopharm Therapeutics Inc

Phase 2/3 Active not recruiting
501 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04712097 2026-05-05

Celestimo

Hoffmann-La Roche

Phase 3 Active not recruiting
478 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

NCT05888493 2026-04-17

LEDA

Novartis

Phase 3 Active not recruiting
109 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

NCT03930953 2026-02-19

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Celgene

Phase 1/2 Active not recruiting
438 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT06097364 2026-02-06

OLYMPIA-2

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
733 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

NCT02390869 2025-12-02

FIL_RENOIR12

Fondazione Italiana Linfomi - ETS

Phase 3 Active not recruiting
128 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

NCT05578976 2025-01-23

EPCORE DLBCL-2

Genmab

Phase 3 Active not recruiting
900 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡